Purpose To determine the distribution of clinically important CYP2C genotypes and allele frequencies in healthy Nordic populations with special focus on linkage disequilibrium. Methods A total of 896 healthy subjects from three Nordic populations (Danish, Faroese, and Norwegian) were genotyped for five frequent and clinically important CYP2C allelic variants: the defective CYP2C8*3, CYP2C9*2, CYP2C9*3, and CYP2C19*2 alleles, and the CYP2C19*17 allele that causes rapid drug metabolism. Linkage disequilibrium was evaluated and CYP2C haplotypes were inferred in the entire population. Results Ten CYP2C haplotypes were inferred, the most frequent of which (49%) was the CYP2C wildtype haplotype carrying CYP2C8*1, CYP2C9*1, and CYP2C19*1. The second most frequent haplotype (19%) is composed of CYP2C19*17, CYP2C8*1, and CYP2C9*1. This predicted haplotype accounts for 99.7% of the CYP2C19*17 alleles found in the 896 subjects. Conclusion CYP2C19*17 is a frequent genetic variant in Nordic populations that exists in strong linkage disequilibrium with wildtype CYP2C8*1 and CYP2C9*1 alleles, which effectively makes it a determinant for a haplotype exhibiting an efficient CYP2C substrate metabolism.
Introduction
Human cytochrome P450 2C (CYP2C) enzymes are responsible for the metabolism of approximately 25% of clinically used drugs [1] and some endogenous substances such as arachidonic acid [2] . The human CYP2C subfamily includes CYP2C8, CYP2C9, CYP2C18, and CYP2C19, which are homologous and share more than 80% amino acid sequence identity [3] . However, only CYP2C8, CYP2C9, and CYP2C19 are considered of clinical importance [4] , since CYP2C18 mRNA is detected at relatively low amounts [5] . The entire CYP2C gene locus spans approximately 500 kb on chromosome 10 with the gene order Cen-2C18-2C19-2C9-2C8-Tel ( Fig. 1) and each of the genes consists of nine exons with conserved exon/ intron boundaries [6] . CYP2C8, CYP2C9, and CYP2C19 exhibit a clinically important genetic polymorphism as a result of single nucleotide polymorphisms (SNPs); www. cypalleles.ki.se.
CYP2C8 catalyzes the metabolism of several clinically used drugs such as the anti-cancer drug paclitaxel, the anti-arrhythmic drug amiodarone, the antidiabetic drug repaglinide, and the thiazolidinediones rosiglitazone and troglitazone [7] . Fourteen allelic variants of CYP2C8 have been described, some of which cause poor metabolism [8] . CYP2C8*3 is a quantitatively and functionally relevant variant allele in the Caucasian population with a reported frequency of 10-23%, but rare or absent in Asian and African populations [5] . CYP2C8*3 is defined by two amino acid substitutions in exon 3 and exon 8 (Table 1) respectively, causing decreased paclitaxel turnover [9] and decreased paclitaxel clearance in vivo [10] .
CYP2C9 is among the most important drugmetabolizing enzymes in humans. It is involved in the metabolism of several important drugs including phenytoin, losartan, (S)-warfarin, tolbutamide, and numerous NSAIDs [11] . Of the 34 allelic variants that have been described [12] , the two clinically most important variant alleles are CYP2C9*2 and CYP2C9*3, which both cause a defective CYP2C9 enzyme (Table 1 ) [13] . The allele frequencies of CYP2C9*2 and CYP2C9*3 are approximately 10-15% and 5-10% respectively in European populations [14] .
CYP2C19 is another important drug-metabolizing enzyme encoded by a highly polymorphic gene [15] . The racemic anticonvulsant drug mephenytoin is the classic probe drug where the 4-hydroxylation of the (S)-enantiomer is catalyzed by CYP2C19. Furthermore, a range of clinically important drugs including diazepam, omeprazole, and other proton pump inhibitors, the antidepressants citalopram, escitalopram, and imipramine, the antimalarial drugs proguanil and chlorproguanil, the β-adrenoceptor blocker propranolol, and the antiplatelet drug clopidogrel are metabolized or bioactivated by CYP2C19. Population studies have shown that individuals who are homozygous for the inactivating allele CYP2C19*2 that leads to a splicing defect (Table 1) are phenotypic poor metabolizers of CYP2C19 substrates [5, 16, 17] . The CYP2C19 poor metabolizers only represent 3-5% of Caucasian populations, but is found in 12-23% of Asian populations [3] . In recent years, much attention has focused on the allele CYP2C19*17, which correlates with high in vivo CYP2C19 activity and was found to be present at an allele frequency of 18% in a Swedish healthy population [18] . The initial finding of a rapid drug metabolism phenotype was later supported by a clear association of lower plasma concentration of omeprazole and escitalopram in subjects homozygous for CYP2C19*17 [19, 20] . Interestingly, CYP2C19*17 also leads to increased bioactivation of the antiplatelet drug clopidogrel, which causes an almost 4-fold higher risk of bleeding complications in CYP2C19*17 homozygotes, but no beneficial antithrombotic effect for patients undergoing percutaneous coronary intervention [21] . As opposed to subjects homozygous for the CYP2C19*1 allele, subjects homozygous for CYP2C19*17 display a very low interindividual variation in CYP2C19 metabolism [19, 22] . The rapid phenotype caused by CYP2C19*17 has been explained by a recruitment of transcription factor(s) by the −806C>T conversion (Table 1) in the gene promoter region that causes an increased transcriptional rate [18] . One hypothesis is that CYP2C19*17 is also a haplotype marker within the CYP2C locus [19] . In fact, haplotype block structures at the CYP2C locus have been described [23, 24] . Almost all subjects carrying CYP2C8*3 also carry CYP2C9*2 and three quarters of all subjects carrying CYP2C9*2 also carry CYP2C8*3 [25] . CYP2C19*2 and CYP2C19*3 have also been shown to be linked with CYP2C18 mutations in Japanese subjects [26] . The aim of this study was to determine important CYP2C genotypes with a special focus on CYP2C19*17 in healthy Nordic populations, and to investigate the linkage disequilibrium between them.
Materials and methods

Samples
The DNA samples from 276 healthy volunteers living around Odense in Denmark and previously genotyped for CYP2C9*2 and CYP2C9*3 [14] , and 311 Faroese samples from healthy volunteers previously genotyped for CYP2C8*3, CYP2C9*2, CYP2C9*3, and CYP2C19*2 [27] were included in this study. Furthermore, DNA samples from 328 Norwegian Caucasian blood donors who had not been genotyped for CYP2C variants were included [28, 29] . Genotyping A total of 915 DNA samples from three different populations were available for genotyping and the aim was to cover the five clinically important CYP2C allelic variants: CYP2C8*, CYP2C9*2, CYP2C9*3, CYP2C19*2, and CYP2C19*17. All 276 DNA samples from Denmark [14] were successfully genotyped for CYP2C8*3, CYP2C19*2, and CYP2C19*17, and all the 311 Faroese samples were successfully genotyped for CYP2C19*17. Of the 328 Norwegian DNA samples, 309 were successfully genotyped for all five CYP2C variants. The analyses were performed using Applied Biosystems TaqMan® SNP genotyping assays (Table 1) according to the guidelines and conducted on an Applied Biosystems StepOne Plus apparatus or an Applied Biosystems 7500 Real Time PCR apparatus.
Statistics
Possible deviation from the Hardy-Weinberg equilibrium was tested for each SNP using Pearson's Chi-squared test with a level of significance of 5%. Overall differences of allele frequencies between the populations were also tested using the Chi-squared test with a level of significance of 5%. "Head to head" comparison between the populations was tested using Fisher's exact test with a level of significance of 5%.
Linkage disequilibrium and haplotype inference
The software Haploview was used to visualize the structure of pair-wise linkage disequilibrium (LD) between the SNPs (in terms of Lewontin's D′) [30] . Individual haplotypes were inferred by use of the five CYP2C SNPs and software package PHASE version 2.1 [31, 32] . This software infers haplotypes from population genotype data using a Bayesian statistical method. We performed PHASE analyses with default settings ten times with different random seeds. Additionally, haplotype frequencies were estimated using the expectation maximization algorithm (EM) in STATA10 (StataCorp; College Station, TX, USA).
Results
We performed genotyping of CYP2C8*3, CYP2C9*2, CYP2C9*3, CYP2C19*2, and CYP2C19*17 in three different Nordic populations. The genotype and allele frequencies in the Danish, Faroese, and Norwegian samples are presented in Table 2 . All SNPs in all three populations were in Hardy-Weinberg equilibrium displaying χ 2 values less than 3.84.
An overall significant difference in allele frequency of CYP2C19*17 was found between the populations (P=0.010). The allele frequency of 15% in the Faroese population (n=311) was lower than the frequency of 20% in the Danish population (n=276; P=0.038) and 22% in the Norwegian population (n=309, P=0.003). No statistically significant difference between the Danish and the Norwegian populations was found. None of the four other SNPs displayed significantly different allele frequencies among the populations.
When analyzing all three populations, none of the 40 subjects homozygous for the rapid CYP2C19*17 allele carried the defective CYP2C8*3, CYP2C9*2 or CYP2C9*3 alleles. In addition, none of the 9 subjects homozygous for CYP2C8*3 carried CYP2C19*17 and none of the 20 subjects homozygous for CYP2C9*2 and/or CYP2C9*3 carried CYP2C19*17.
The linkage disequilibrium between the five SNPs analyzed as based on Haploview calculations is visualized in Fig. 2 . The calculations show complete LD (D'=1) among CYP2C19*17 and the four other allelic variants. Complete linkage disequilibrium was also observed among CYP2C19*2 and the two CYP2C9 alleles CYP2C9*2 and CYP2C9*3. The analysis also displays strong linkage disequilibrium between CYP2C9*2 and CYP2C8*3 (D'=0.92).
Ten CYP2C haplotypes were inferred ( Table 3 ). The CYP2C haplotype frequencies predicted by PHASE and STATA were almost identical. Six of the haplotypes (Nos.1-5 and 9) account for 99% of the haplotypes. The most frequent haplotype (No. 1) with an inferred frequency of 49% carries the CYP2C8*1, CYP2C9*1, and CYP2C19*1 alleles. The second most frequent haplotype (No. 2) with an inferred frequency of 19% is composed of CYP2C19*17, CYP2C8*1, and CYP2C9*1 wildtype alleles, and represents 99.7% (342 out of 343) of all predicted CYP2C19*17-containing haplotypes. In one Norwegian subject, a single variant haplotype with CYP2C19*17 in combination with CYP2C8*3 was inferred, thus leading to an estimated haplotype frequency of <0.001 in the total study material containing 896 subjects ( Table 2 ). The previously reported linkage disequilibrium between CYP2C9*2 and CYP2C8*3 presented by Yasar et al. [25] was also supported by our data. In detail, 94% (144 out of 154) of the haplotypes with CYP2C8*3 were also predicted to carry CYP2C9*2, and 79% (144 out of 183) of the haplotypes with CYP2C9*2 were also predicted to carry CYP2C8*3. 
Discussion
This study provides support to the hypothesis of a linkage disequilibrium between CYP2C19*17 and functional CYP2C alleles. This hypothesis was first expressed by Baldwin et al. [19] , but was based on relatively limited data. Further indications can be found by reviewing the genotype information presented by Rudberg et al. [22] . In the present study, we found that CYP2C19*17 is predicted to be almost exclusively present together with wildtype alleles of CYP2C8 and CYP2C9, thus mediating rapid metabolism of CYP2C19 substrates and normal (mostly referred to as extensive) metabolism of CYP2C8 and CYP2C9 substrates. The prediction of one haplotype out of the 343 CYP2C19*17-containing haplotypes that exists in combination with CYP2C8*3 must be recognized. However, the existence of these two variants on separate haplotypes is still a theoretical possibility, although predicted to be rare. Nevertheless, the clinical picture is clear, showing that subjects with CYP2C19*17, which confers a rapid metabolism of CYP2C19 substrates, are likely to display extensive metabolic capacity toward other CYP2C substrates.
This study also confirms the linkage between CYP2C9*2 and CYP2C8*3 with similar correlation percentages to those previously shown by Yasar et al. [25] . Thus, poor metabolizers of CYP2C9 substrate drugs are also likely to metabolize CYP2C8 substrates poorly. It is interesting to note that across the three genes CYP2C19, CYP2C9, and CYP2C8, the five SNPs examined occur in six distinct haplotypes 99% of the time and further that these haplotypes exclusively carry none or just a single SNP except for haplotype No. 9, which is characterized by two SNPs. This is in accordance with the notion that SNPs are introduced to the genome as a single mutation occurring at a single point in time in a single individual and vertically propagated to the population. In future pharmacogenetic studies it might be worthwhile considering these haplotypes as an alternative to the individual SNPs, as this approach might offer a more powerful design that can possibly reveal effects of interplay between cis variants, which is impossible in a simple analysis of individual SNPs.
The current study supports the general assumption that the Nordic populations have a relatively similar distribution of cytochrome P450 genotypes. The CYP2C19*17 allele was first reported in Swedes with a frequency of 18% [18] , but a recent study reported a Swedish allele frequency of 20% [33] . The Norwegian CYP2C19*17 allele frequency of 22% in the current study of healthy volunteers is identical to the reported frequency in 166 Norwegian psychiatric patients [22] , and similar to that observed in the Danish subjects of the present study (20%). The Faroese population had a statistically significant lower allele frequency of 15%, but no correction for multiple testing was made. A similar allele frequency of 20% was found in a Greek population [34] and in African populations: 18% in Ethiopians [18] and 17% in Ugandans [35] . In Asian populations very low frequencies of CYP2C19*17 have been reported: 4% in Chinese [18] , 1% in Japanese [36] , and 0.3% in Koreans [33] . On the other hand, the frequency is apparently higher in Central Europe: 25% in a German breast cancer population [37] and 28% in a population of Polish peptic ulcer patients [38] . Overall, CYP2C19*17 must be considered prevalent in all the Nordic populations studied here, and the frequency of subjects homozygous for CYP2C19*17 only ranged from 3.5 to 5.1% in the material studied.
In conclusion, we have in the current study identified a common haplotype in the Nordic population carrying the CYP2C19*17, CYP2C8*1, and CYP2C9*1 alleles, thus representing a haplotype encoding efficient metabolism of all drugs that are substrates for CYP2C enzymes. The CYP2C19*17 genotype could thus be used as a determinant for extensive metabolism of CYP2C substrates in Nordic subjects.
